Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advance
Go back to Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advance| Johnson & Johnson (NYSE: JNJ) | Delayed: 275.23 -3.2 (1.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $278.43 | 52 Week High | $126.07 | |||
| Open | $275.13 | 52 Week Low | $94.28 | |||
| Day High | $277.80 | P/E | 57.22 | |||
| Day Low | $274.75 | EPS | $4.81 | |||
| Volume | 4,320,320 | |||||
